With new data, AstraZeneca makes the case for its BTK inhibitor in a first-line setting
Combined with chemotherapy and immunotherapy, AstraZeneca’s Calquence reduced the risk of disease progression or death by 27% compared to placebo and chemoimmunotherapy in first-line mantle …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
